Oxopyridinyl pharmaceutical compositions and methods for use
First Claim
Patent Images
1. A compound of the formula:
-
where each of X, X′
, Y′ and
Y″
are carbon bonded to a substituent species selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, F, Cl, Br, I, NR′
R″
, CF3, OH, CN, NO2, C2R′
, SH, SCH3, N3, SO2CH3, OR′
, (CR′
R″
)qOR′
, O—
(CR′
R″
)qC2R′
, SR′
, C(═
O)NR′
R″
, NR′
C(═
O)R″
, C(═
O)R′
, C(═
O)OR′
, OC(═
O)R′
, (CR′
R″
)qOCH2C2R′
, (CR′
R″
)qC(═
O)R′
, (CR′
R″
)qC(CHCH3)OR′
, O(CR′
R″
)qC(═
O)OR′
, (CR′
R″
)qC(═
O)NR′
R″
, (CR′
R″
)qNR′
R″
, CH═
CHR′
, OC(═
O)NR′
R″ and
NR′
C(═
O)OR″
where q is an integer from 1 to 6 and R′ and
R″
are individually hydrogen, alkyl, cycloalkyl, or an aromatic group-containing species selected from the group consisting of phenyl, substituted phenyl, benzyl, and substituted benzyl;
m and n are integers such that the sum of m plus n is 2 or 3;
Z and Z′
are individually hydrogen or methyl; and
E, EI, EII and EIII are individually hydrogen or methyl.
0 Assignments
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropoxy-1-oxopyridin)yl)]-4-penten-2-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine.
-
Citations
15 Claims
-
1. A compound of the formula:
-
where each of X, X′
, Y′ and
Y″
are carbon bonded to a substituent species selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, F, Cl, Br, I, NR′
R″
, CF3, OH, CN, NO2, C2R′
, SH, SCH3, N3, SO2CH3, OR′
, (CR′
R″
)qOR′
, O—
(CR′
R″
)qC2R′
, SR′
, C(═
O)NR′
R″
, NR′
C(═
O)R″
, C(═
O)R′
, C(═
O)OR′
, OC(═
O)R′
, (CR′
R″
)qOCH2C2R′
, (CR′
R″
)qC(═
O)R′
, (CR′
R″
)qC(CHCH3)OR′
, O(CR′
R″
)qC(═
O)OR′
, (CR′
R″
)qC(═
O)NR′
R″
, (CR′
R″
)qNR′
R″
, CH═
CHR′
, OC(═
O)NR′
R″ and
NR′
C(═
O)OR″
where q is an integer from 1 to 6 and R′ and
R″
are individually hydrogen, alkyl, cycloalkyl, or an aromatic group-containing species selected from the group consisting of phenyl, substituted phenyl, benzyl, and substituted benzyl;
m and n are integers such that the sum of m plus n is 2 or 3;
Z and Z′
are individually hydrogen or methyl; and
E, EI, EII and EIII are individually hydrogen or methyl.- View Dependent Claims (2, 3, 4, 5)
-
-
6. A pharmaceutical composition comprising an amount of a compound of the formula,
in association with a pharmaceutically acceptable carrier where each of X, X′ - , Y′ and
Y″
are carbon bonded to a substituent species selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, F, Cl, Dr, I, NR′
R″
, CF3, OH, CN, NO2, C2R′
, SH, SCH3, N3, SO2CH3, OR′
, (CR′
R″
)qOR′
, O—
(CR′
R″
)qC2R′
, SR′
, C(═
O)NR′
R″
, NR′
C(═
O)R″
, C(═
O)R′
, C(═
O)OR′
, OC(═
O)R′
, (CR′
R″
)qOCH2C2R′
, (CR′
R″
)qC(═
O)R′
, (CR′
R″
)qC(CHCH3)OR′
, O(CR′
R″
)qC(═
O)OR′
, (CR′
R″
)qC(═
O)NR′
R″
, (CR′
R″
)qNR′
R″
, CH═
CHR′
, OC(═
O)NR′
R″ and
NR′
C(═
O)OR″
where q is an integer from 1 to 6 and R′ and
R″
are individually hydrogen, alkyl, cycloalkyl, or an aromatic group-containing species selected from the group consisting of phenyl, substituted phenyl, benzyl, and substituted benzyl;
m and n are integers such that the sum of m plus n is 2 or 3;
Z and Z′
are individually hydrogen or methyl; and
E, EI, EII and EIII are individually hydrogen or methyl. - View Dependent Claims (7, 8, 9, 10)
- , Y′ and
-
11. A method for treating a disorder characterized by alteration in normal neurotransmitter release comprising administering to a subject in need thereof an effective amount of a compound of the formula:
-
where each of X, X′
, Y′ and
Y″
are carbon bonded to a substituent species selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, F, Cl, Br, I, NR′
R″
, CF3, OH, CN, NO2, C2R′
, SH, SCH3, N3, SO2CH3, OR′
, (CR′
R″
)qOR′
, O—
(CR′
R″
)qC2R′
, SR′
, C(═
O)NR′
R″
, NR′
C(═
O)R″
, C(═
O)R′
, C(═
O)OR′
, OC(═
O)R′
, (CR′
R″
)qOCH2C2R′
, (CR′
R″
)qC(═
O)R′
, (CR′
R″
)qC(CHCH3)OR′
, O(CR′
R″
)qC(═
O)OR′
, (CR′
R″
)qC(═
O)NR′
R″
, (CR′
R″
)qNR′
R″
, CH═
CHR′
, OC(═
O)NR′
R″ and
NR′
C(═
O)OR″
where q is an integer from 1 to 6 and R′ and
R″
are individually hydrogen, alkyl, cycloalkyl, or an aromatic group-containing species selected from the group consisting of phenyl, substituted phenyl, benzyl, and substituted benzyl;
m and n are integers such that the sum of m plus n is 2 or 3;
Z and Z′
are individually hydrogen or methyl; and
E, EI, EII and EIII are individually hydrogen or methyl.- View Dependent Claims (12, 13, 14, 15)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeTargacept, Inc. (Catalyst Biosciences, Inc.)
-
Original AssigneeTargacept, Inc. (Catalyst Biosciences, Inc.)
-
InventorsByrd, Gary Dwight, Bhatti, Balwinder Singh, Miller, Craig Harrison, Schmitt, Jeffrey Daniel, Dull, Gary Maurice, Lynm, Dwo, Caldwell, William Scott
-
Primary Examiner(s)Rotman, Alan L.
-
Assistant Examiner(s)DESAI, RITA J
-
Application NumberUS09/570,226Time in Patent Office865 DaysField of Search546/290, 546/298, 546/345, 546/347, 546/329, 514/358, 514/357US Class Current514/358CPC Class CodesC07D 213/38 having only hydrogen or hyd...C07D 213/65 attached in position 3 or 5C07D 213/70 Sulfur atomsC07D 213/73 Unsubstituted amino or imin...C07D 213/74 Amino or imino radicals sub...C07D 213/82 in position 3C07D 213/89 with hetero atoms directly ...C07D 239/42 One nitrogen atom nitro rad...
